Scottish Enterprise

EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

Retrieved on: 
Thursday, April 4, 2024
Cirrhosis, Scottish Enterprise, Partnership, Patient, Irritable bowel syndrome, Bank, Standard of care, Therapy, Hepatic encephalopathy, Scottish National Investment Bank

GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors.

Key Points: 
  • GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors.
  • Existing investors including Scottish Enterprise and many of the Company’s private investors also participated.
  • Dr James McIlroy, CEO of EnteroBiotix, said: “This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome.
  • It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market.

CALCIVIS® to Launch Revolutionary New Bioluminescent Dental Imaging System in the US After Securing Final Stage Food and Drug Administration Pre-Market Approval (PMA)

Retrieved on: 
Thursday, January 18, 2024
Other Manufacturing, Medical Supplies, Other Science, Technology, FDA, Engineering, Manufacturing, Mobile, Wireless, Consumer, Medical Devices, Venture Capital, Health Technology, Finance, Dental, Professional Services, Biotechnology, Other Technology, Health, Hardware, Other Consumer, Science, Patient, Multimedia, Radioactive decay, Map, Scottish Enterprise, Luminescence, PMA, Marketing, Financial management, Dentistry

The business filed a PMA supplement with the FDA for enhancements to its imaging system last year and the new ergonomic, wireless, handheld imaging device is now approved for commercialization.

Key Points: 
  • The business filed a PMA supplement with the FDA for enhancements to its imaging system last year and the new ergonomic, wireless, handheld imaging device is now approved for commercialization.
  • The two executives have extensive experience in the dental and medical device space.
  • The US roll out will begin with a limited release launch in the greater Boston area in early 2024.
  • An integrated intra-oral sensor within the Calcivis imaging device immediately detects the luminescence (light flash) and presents clinicians with a chairside demineralization map.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

Retrieved on: 
Tuesday, November 14, 2023
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Investment, Therapy, Gram, Patient, Medicine, University of Strathclyde, Death, University of Oxford, Laboratory, Klebsiella pneumoniae, GSK, Bacteria, Collateral damage, AMR, Klebsiella, University, Pseudomonas aeruginosa, University of Glasgow, Innovation, Physician, Scottish Enterprise, Pharmaceutical industry, Antibiotics, Entrepreneurship, Bacteriocin

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Key Points: 
  • Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
  • **
    Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins.
  • Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics.
  • “This seed funding is testament to the promise of Glox Therapeutics’ precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors.

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

Retrieved on: 
Wednesday, September 13, 2023
European Investment Fund, Camp, Kidney failure, Drug development, University, Therapy, AMP, Polyuria, Sofinnova, Cell proliferation, Autosomal dominant polycystic kidney disease, PKD2, Cyst, Patient, University of Strathclyde, PKD1, Series, AICA ribonucleotide, Kidney, Growth, ADPKD, Scottish Enterprise, IND, Disease, Pharmaceutical industry

The Company will use the proceeds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate.

Key Points: 
  • The Company will use the proceeds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate.
  • It affects over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60.
  • The disease is caused predominantly by mutations in the PKD1 or PKD2 gene and is characterized by uncontrolled growth of fluid-filled cysts in the kidney.
  • Robust in vitro and disease model data show significant efficacy across all disease endpoints, including a reduction in cyst number and kidney volume.

Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections

Retrieved on: 
Thursday, June 1, 2023
Chronic obstructive pulmonary disease, COPD, Scottish Enterprise, RTI International, Patient, Pharmaceutical industry, Vaccine

Pneumagen secured the latest funds from existing investors, Thairm Bio and Scottish Enterprise, new investor Esperante Ventures, the directors, as well as several US based investors.

Key Points: 
  • Pneumagen secured the latest funds from existing investors, Thairm Bio and Scottish Enterprise, new investor Esperante Ventures, the directors, as well as several US based investors.
  • The latest funding round will enable the company to advance the clinical development of Neumifil for individuals with COPD suffering from virus induced exacerbations.
  • Neumifil is currently being evaluated in a Phase 2a proof of concept human challenge study in healthy participants subsequently infected with influenza virus.
  • “We were attracted by the quality of Pneumagen’s leadership and multiple milestones that Douglas and the Pneumagen team have delivered as they work to position Neumifil as a treatment option for respiratory tract infections.”

Star Refrigeration reaches 2023 final of VIBES Scottish Environment Business Awards

Retrieved on: 
Wednesday, May 31, 2023
Ethos, Carbon, SEPA, Private sector, SDG, Food, EV, United Nations, Partnership, Climate, Tourism, Decent work, Refrigeration, Intelligence, Sustainable Development Goal 12, Sustainable Development Goals, SECR, Certification, EVS, Scottish Environment Protection Agency, Star, Youth Business Scotland, Bristol Harbour, Streamlining Energy Efficiency for Schools Act, Scottish Government, NatureScot, Energy Saving Trust, Heat, Scottish Enterprise, CO2, Pearson, Clydebank, Heating, ventilation, and air conditioning, Renewable energy, Online shopping, South of Scotland Enterprise

GLASGOW, UK, May 31, 2023 /PRNewswire-PRWeb/ -- Leading natural refrigeration and heating experts, Star Refrigeration, have been shortlisted as a finalist for the 2023 VIBES Scottish Environment Business Awards, which celebrate companies who achieve a balance between economic success and environmental sustainability. The 2023 shortlist was announced last week ahead of the awards ceremony taking place in November.

Key Points: 
  • GLASGOW, UK, May 31, 2023 /PRNewswire-PRWeb/ -- Leading natural refrigeration and heating experts, Star Refrigeration, have been shortlisted as a finalist for the 2023 VIBES Scottish Environment Business Awards, which celebrate companies who achieve a balance between economic success and environmental sustainability.
  • Dave Pearson, Group Sustainable Development Director at Star Refrigeration, said, "We are delighted to be shortlisted in this award.
  • The VIBES Scottish Environment Business Awards are a partnership between Scottish Environment Protection Agency (SEPA), The Scottish Government, Energy Saving Trust, Highland & Islands Enterprise, Scottish Enterprise, South of Scotland Enterprise, Scottish Water, Zero Waste Scotland and NatureScot.
  • For more information about the VIBES 2023 Scottish Business Environment Awards, visit https://www.vibes.org.uk/
    For more information about Star Refrigeration's sustainable developments, visit https://www.star-ref.co.uk/

Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round

Retrieved on: 
Wednesday, April 26, 2023
Health, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GSK, IPO, Hepatitis, Partnership, University, Urinary tract infection, HIV, SARS-CoV-2, Dermatitis, Infection, ICL, Skin, CTA, Atopic dermatitis, Multimedia, Respiratory syncytial virus, Psoriasis, RSV, University of Strathclyde, Dog, Series, Preclinical development, Growth, Immunology, Scottish Enterprise, Therapy, VC, Eos, BioCity Nottingham, ILC, Vaccine, Management, Pharmaceutical industry

Scottish biotech ICL Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round, and is on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections including SARS-CoV-2.

Key Points: 
  • Scottish biotech ICL Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round, and is on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections including SARS-CoV-2.
  • An additional £2 million round led by existing investors was subsequently completed in Q4 of 2022.
  • One of Scotland’s most pioneering biotechs, ILC is also expected to embark on a Series A investment round over the next twelve months, with a view to a possible post-investment round IPO.
  • ILC has appointed Dr Owain Millington as Vice President and Head of Preclinical Development, who has a long career in life sciences leadership teams.

30 Technology’s Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications

Retrieved on: 
Wednesday, April 19, 2023
Infection, COPD, Social work, LSE, Research and development, Therapy, Powder, CTEC, Stifel, Respiratory disease, Nitric oxide, Health, Immunity, Research, Cystic fibrosis, National Institute of General Medical Sciences, IP, Fungus, Sale, CN v Secretary of State for Health and Social Care, Divestment, NO, Patent, Patient, Ophthalmology, Convatec, Bacteria, NHS, Burns, Rare, Scottish Enterprise, Virus, Dentistry, Pharmaceutical industry, Vaccine, Bronchiectasis

London, UK, 19 April 2023 – 30 Technology, the world leader in clinical nitric oxide generation technology for health care, today announced that it has completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC).

Key Points: 
  • London, UK, 19 April 2023 – 30 Technology, the world leader in clinical nitric oxide generation technology for health care, today announced that it has completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC).
  • As part of the transaction, a small team from 30 Technology will transfer across to Convatec.
  • Syd Hanna, Group Executive Director of 30 Technology commented: “This transaction validates 30 Technology’s transformational approach to unlock the potential of nitric oxide to treat a range of infections with a durable and safe treatment.
  • Stifel acted as financial advisor and Goodwin Procter provided legal counsel to 30 Technology.

Calcivis Targets US Expansion After Securing FDA PMA Approval

Retrieved on: 
Wednesday, March 8, 2023
Biotechnology, FDA, Medical Devices, Health, Dental, COVID-19, Archangel, Radioactive decay, Accreditation, Multimedia, PMA, Dentist, Safety, Scottish Enterprise, Map, Luminescence, Medical device, Dentistry, Pharmaceutical industry, Entrepreneurship

PMA approval is only awarded after a statutory process of scientific review to ensure the efficacy and safety of medical devices.

Key Points: 
  • PMA approval is only awarded after a statutory process of scientific review to ensure the efficacy and safety of medical devices.
  • PMA accreditation will allow Edinburgh-based Calcivis to tap into the multi-billion dollar US dental market.
  • An integrated intra-oral sensor within the Calcivis imaging device immediately detects the luminescence (light flash) and presents clinicians with a chair-side demineralisation map.
  • Adam Christie, CEO at Calcivis, said: “It’s been a long process with delays caused by Covid restrictions, so we’re very pleased to have achieved PMA status.

Dxcover Raises $11.9m in Series A and Grant Funding to Accelerate Liquid Biopsy to Market

Retrieved on: 
Wednesday, February 1, 2023
Oncology, Health, Other Health, Clinical Trials, Research, Science, Biotechnology, Knowledge, Brain, CE, Colorectal cancer, Scottish Enterprise, European Innovation Council, Cancer, Algorithm, Patient, Artificial intelligence, University of Strathclyde, University, Death, Survival, Disease, Liquid biopsy, Growth, Quality of life, Partner (business rank), Hereditary nonpolyposis colorectal cancer, Pharmaceutical industry, Medical imaging, Series

Dxcover Limited , a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today announced it has raised $11.9 (£9.7) million in Series A and grant financing.

Key Points: 
  • Dxcover Limited , a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today announced it has raised $11.9 (£9.7) million in Series A and grant financing.
  • The funding will support the ongoing development of the Dxcover® Liquid Biopsy Platform for the detection of early-stage cancers, including brain and colorectal cancers.
  • Boston-based life science investor Mark Bamforth of Thairm Bio also joined the round as Dxcover continues to develop its U.S. network.
  • Dxcover received a grant of $2.7 (£2.2) million from the European Innovation Council, following a rigorous competitive process.